March 27, 2025 02:31 PM EDT
R&D

Mer­ck de­tails in­jectable Keytru­da da­ta as it awaits au­tumn FDA de­ci­sion

Lei Lei Wu

News Reporter

Mer­ck shared Phase 3 da­ta show­ing that an in­jectable ver­sion of its block­buster can­cer drug Keytru­da is com­pa­ra­ble to the ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Fir­ings sweep across FDA as for­mer lead­ers lament drug agen­cy's gut­ting

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

RNA edit­ing start­up rais­es $155M to bring liv­er and lung dis­ease ther­a­py in­to clin­ic

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times